Ahmed Mohamed A. Ibrahim1,*, Mohammed Hussein Abdullah2, Hadia Abass E. Ahmed2
1- Dept. of Pathology, Faculty of Medicine, Shendi University, Shendi, Sudan, *firstname.lastname@example.org
2- Dept. of Microbiology, Faculty of Medical Laboratory Sciences, Shendi University, Shendi, Sudan
Escherichia coli (E. coli) producing extended-spectrum β-lactamase (ESBL) has become prevalent globally, thus severely limiting the therapeutic management. This study was carried out to determine the prevalence and susceptibility pattern of ESBL producing E. coli isolates among urinary isolates at Soba University Hospital, Sudan, from March to December 2018. A hundred E. coli urinary isolates were obtained; ESBL production and antimicrobial susceptibility were estimated using CLSI guidelines. ESBL phenotype prevalence among the hundred study isolates is, 56%. Most of the ESBL isolates are from inpatient, 64.7% of 79 while 23.8 % of 21 are from outpatient (P = 0.0008), the frequency of ESBLs production is significantly higher in females, 66.7% (42/63) than males 37.8% (14/37) (P = 0.005), however, there is no significant difference among age groups. The result of ESBL producers E. coli antibiogram reveals resistant to cefotaxime, 100%, ceftriaxone,100%, ceftazidime, 98.2% and norfloxacine, 89.3%, while the resistance of non ESBL-producers isolates are to co-trimoxazol, 54.5%, nor floxacine, 52.3% and tetracycline, 43.2%. However, the maximum sensitivity of both ESBL-producers and non-producers isolates are seen for imipenem, 100% vs 100 percentage, followed by piperacillin/tazobactum, 80.4% vs 97.7% and amikacin, 42.9% vs 88.6%. In conclusion, results reveal the prevalence of ESBLs among uropathogenic E. coli is high in Sudan, thus, further consideration should be needed for control.
Keywords: E. coli, ESBL, multi-drug resistance